HC Wainwright reiterated their buy rating on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) in a report ...

Analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Nuvectis Pharma in a note issued to investors on Tuesday, February 25th. HC Wainwright analyst J. Pantginis expects that ...

LAVA Therapeutics reviews strategic options amid cost cuts. HC Wainwright downgrades stock, citing uncertainties over LAVA-1266 and possible business shifts.

SoundHound AI's speech recognition model "outperformed" Google and OpenAI during Q4 as it announced a new seven-figure energy ...

Fintel reports that on February 27, 2025, HC Wainwright & Co. downgraded their outlook for LAVA Therapeutics N.V.

Novavax Inc (NASDAQ:NVAX) reported fourth-quarter 2024 sales of $88.31 million, compared to $291 million a year, beating the ...

Minerva Neurosciences Inc (NERV) is expected to report for 4Q. NeuroMetrix Inc (NURO) is expected to report for 4Q. Nikola Corp (NKLAQ) is expected to report for 4Q. Norwegian Cruise Line Holdings Ltd ...

Fintel reports that on February 26, 2025, HC Wainwright & Co. downgraded their outlook for Geron (NasdaqGS:GERN) from Buy to ...

Pemgarda has a standing emergency use authorization as a prophylaxis for immunocompromised patients, but FDA’s stringent ...

We recently published a list of 12 Best Robinhood Stocks to Buy Under $20. In this article, we are going to take a look at ...

increases in stock price and/or market capitalization unrelated to the performance of the business including sales under the ATM Agreement with HC Wainwright, conversion of the Series V, the exercise ...

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Cybin (CYBN – Research Report) today and set a price target of $190.00. The company’s shares closed yesterday at $9.83.